6533b85bfe1ef96bd12bbf82
RESEARCH PRODUCT
Evaluation of Anti-SARS-Cov-2 S-RBD IgG Antibodies after COVID-19 mRNA BNT162b2 Vaccine
Matteo VidaliRosaria Vincenza Giglio 6 Concetta ScazzoneBruna Lo SassoLuisa AgnelloGiulia BivonaMarcello CiaccioCaterina Maria GambinoAnna Maria Ciacciosubject
0301 basic medicineMedicine (General)Coronavirus disease 2019 (COVID-19)Chemiluminescence immunoassayvirusesSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Clinical BiochemistryAsymptomaticArticleAntibodies03 medical and health sciencesR5-9200302 clinical medicineMedicineKineticMessenger RNAbiologySARS-CoV-2business.industryVaccinationvirus diseasesCOVID-19spikeVaccination030104 developmental biologyAntibody response030220 oncology & carcinogenesisImmunologybiology.proteinmedicine.symptomAntibodybusinessImmunosurvellianceVaccineS-RBD IgGdescription
(1) Background: The evaluation of anti-spike protein receptor-binding domain (S-RBD) antibodies represents a useful tool to estimate the individual protection against Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2) infection
year | journal | country | edition | language |
---|---|---|---|---|
2021-06-22 | Diagnostics |